about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityDendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cellsIndependent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells.Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity.Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.Inhibiton of tumor-derived prostaglandin-e2 prevents the induction of human myeloid-derived suppressor cells (MDSCs) and rescues anti-tumor immunityAdaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γInhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activityMesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function
P50
Q26773135-D8CB4C6B-7F1D-406E-BD77-3A033842A4C4Q34467270-D2838C7F-C66D-4B36-B3CD-F2F776BB7F19Q36388560-E9F3A7BF-C0E1-4CB2-87B3-0625DD20A941Q37460236-1EAF43A0-4A3A-4D73-B8ED-8C3103AC52A9Q38260461-98932848-D616-4B27-B7A7-CDB991447599Q38672403-A1C6500D-BE9D-4DAE-A70A-BCE180ABC409Q39149515-EFC88DDC-0B24-40DE-AF70-F773653CAA99Q39179377-D14AEE57-6E17-4CA6-B271-C4F2184BF363Q39402352-C6B30F58-5C9B-4F65-BE0B-34F232F0A061Q40101568-4B5A4209-73EA-4A04-B91B-4C96D4603D39Q40583098-5CCC232C-25B9-4E1B-8DC5-5121DC2673F7Q52755645-0EB3176B-2484-4654-971C-40AFE9FC166EQ59394985-B9A5D408-D3B2-4468-B82B-B88316862C3CQ64998492-3F9848B2-4AA8-4B43-9A6F-04C4C0CA28F4Q85007169-B7599E46-F29A-4B6D-A8E3-A36879C3BBAAQ88035142-64D1CBC5-78ED-4055-ACEF-F1FAFD9E8279Q89655216-67A51124-0A7C-4486-BD55-E9897CF2F0C8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dhifaf Sarhan
@ast
Dhifaf Sarhan
@en
Dhifaf Sarhan
@es
Dhifaf Sarhan
@nl
Dhifaf Sarhan
@sl
type
label
Dhifaf Sarhan
@ast
Dhifaf Sarhan
@en
Dhifaf Sarhan
@es
Dhifaf Sarhan
@nl
Dhifaf Sarhan
@sl
altLabel
Dhifaf Sarhan
@en
prefLabel
Dhifaf Sarhan
@ast
Dhifaf Sarhan
@en
Dhifaf Sarhan
@es
Dhifaf Sarhan
@nl
Dhifaf Sarhan
@sl
P106
P31
P496
0000-0003-0196-4496